Correlation Between Syndax Pharmaceuticals and Transcode Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and Transcode Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and Transcode Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Syndax Pharmaceuticals and Transcode Therapeutics, you can compare the effects of market volatilities on Syndax Pharmaceuticals and Transcode Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of Transcode Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and Transcode Therapeutics.

Diversification Opportunities for Syndax Pharmaceuticals and Transcode Therapeutics

0.63
  Correlation Coefficient

Poor diversification

The 3 months correlation between Syndax and Transcode is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and Transcode Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Transcode Therapeutics and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with Transcode Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Transcode Therapeutics has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and Transcode Therapeutics go up and down completely randomly.

Pair Corralation between Syndax Pharmaceuticals and Transcode Therapeutics

Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to under-perform the Transcode Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Syndax Pharmaceuticals is 2.97 times less risky than Transcode Therapeutics. The stock trades about -0.08 of its potential returns per unit of risk. The Transcode Therapeutics is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  957.00  in Transcode Therapeutics on September 17, 2024 and sell it today you would lose (237.00) from holding Transcode Therapeutics or give up 24.76% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Syndax Pharmaceuticals  vs.  Transcode Therapeutics

 Performance 
       Timeline  
Syndax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Syndax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Transcode Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Transcode Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Transcode Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Syndax Pharmaceuticals and Transcode Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Syndax Pharmaceuticals and Transcode Therapeutics

The main advantage of trading using opposite Syndax Pharmaceuticals and Transcode Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, Transcode Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Transcode Therapeutics will offset losses from the drop in Transcode Therapeutics' long position.
The idea behind Syndax Pharmaceuticals and Transcode Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Stocks Directory
Find actively traded stocks across global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Fundamental Analysis
View fundamental data based on most recent published financial statements